Agree Realty(US:ADC) Prnewswire·2024-10-31 11:15Core Viewpoint - ADC Therapeutics SA is set to report its third quarter 2024 financial results and provide operational updates during a conference call on November 7, 2024 [1]. Company Overview - ADC Therapeutics is a commercial-stage global leader in the field of antibody drug conjugates (ADCs) [3]. - The company is focused on transforming treatment paradigms for patients with hematologic malignancies and solid tumors through its proprietary ADC technology [3]. Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4]. - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy, alongside multiple ADCs in ongoing clinical and preclinical development [4]. Conference Call Details - The conference call will take place at 8:30 a.m. EST, and participants can register in advance or join 10 minutes before the event [2]. - A live webcast will be available on the ADC Therapeutics website, with an archived version accessible for 30 days post-call [2].